

# The relationship of uric acid levels with lipid parameters and body mass index in healthy individuals\*

Nurcan Akbaş Güneş<sup>®</sup>

Department of Family Medicine, Faculty of Medicine, Bolu Abant İzzet Baysal University, Bolu, Türkiye.

\* This study was presented as an oral presentation at the 19th National Family Medicine Congress which was held on October 29- November 01, 2020, at Online Congress, Ankara, Türkiye.

**Cite as:** Akbaş Güneş N. The relationship of uric acid levels with lipid parameters and body mass index in healthy individuals. Northwestern Med J. 2024;4(1):48-52.

## ABSTRACT

**Aim:** The relationship between hypertension, dyslipidemia, atrial fibrillation, obesity, and diabetes, which are cardiovascular risk factors, and a high serum uric acid level has been reported in the literature. However, the effectiveness of the adjustments to be made in uric acid levels on these diseases has not been clearly demonstrated yet. This study focuses on the relationship between serum uric acid levels and body mass index and lipid profile of healthy individuals.

**Methods:** Records of healthy volunteers obtained from the Family Medicine outpatient clinic were reviewed. Body mass index, serum uric acid, low-density lipoprotein, high-density lipoprotein, total cholesterol and triglyceride levels were analyzed retrospectively.

**Results:** Data from a total of 126 participants (90 female [71.4%], 36 male [28.6%]) were examined. Serum uric acid levels were correlated with body mass index ( $p=0.000$ ,  $r=0.571$ ) and serum triglyceride levels ( $p=0.001$ ,  $r=0.397$ ). No correlation was found between serum uric acid and lipoproteins and total cholesterol.

**Conclusion:** This study found that increased serum uric acid levels are associated with increased body mass index and increased serum triglyceride levels. Additionally, serum uric acid levels were higher in men. We recommend the routine assessment of uric acid levels during periodic health examinations.

**Keywords:** Body mass index, triglyceride, uric acid

**Corresponding author:** Nurcan Akbaş Güneş **E-mail:** drnurak@hotmail.com

**Received:** 28.11.2022 **Accepted:** 18.04.2023 **Published:** 30.01.2024

Copyright © 2024 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the [Creative Commons Attribution License \(CC BY\)](#) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

## INTRODUCTION

Uric acid (UA) is the end product of the catabolism of adenosine and guanosine nucleotides (1). In recent years, the acceptance of UA levels as an independent risk factor for cardiovascular diseases has been discussed. Studies have found that elevated UA levels are associated with comorbidities such as hypertension, atrial fibrillation, dyslipidemia, coronary artery disease, obesity, and diabetes (2). It has also been shown that UA is associated with mortality in all patients with coronary artery disease (3). There are studies in the literature stating the opposite of these studies (4).

Hyperuricemia is defined as higher than 6.8 mg/dL, and as it rises, urate crystals begin to accumulate (5). European guidelines recommend UA level as  $\leq 6$  mg/dL (6). Although elevated UA levels are most commonly associated with gout disease, it has also been associated with hypertension, vascular diseases, renal disease, and cardiovascular events. UA crystals accumulate in the urinary tract and human tissues and cause diseases. In addition, UA has an antioxidant and pro-inflammatory mechanism of action (7).

Asymptomatic hyperuricemia is a high ( $>6.8$  mg/dL) UA level without signs of crystal deposition disease (8). Although asymptomatic hyperuricemia is not considered a disease, it is considered a predisposing factor (9). The need for treatment and whether it can reduce the risk of comorbidity have not been clarified yet (10,11).

In this study, we aimed to evaluate the relationship between UA levels and body mass index (BMI), triglyceride, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol levels in healthy individuals.

## MATERIAL AND METHODS

### Study design

The necessary permission was obtained from the Bolu Abant İzzet Baysal University Clinical Research Ethics

Committee (2020/284) for our study. We designed this study as a cross-sectional study.

One hundred and twenty-six healthy participants who applied to the family medicine outpatient clinic of İzzet Baysal Training and Research Hospital between October 2019 and March 2020 were included in the study. Patients with comorbidities requiring continuous medication were excluded from the study.

Height and weight serum uric acid levels measured after 12 hours of fasting, LDL, HDL, total cholesterol, triglyceride levels, and other hematological parameters were evaluated retrospectively. Body mass index ( $\text{kg}/\text{m}^2$ ) was calculated by dividing weight (kg) by the square of height ( $\text{m}^2$ ).

### Statistical analysis

SPSS version 25.0 was used for the statistical analysis of the data. Arithmetic mean  $\pm$  standard deviation was calculated for numerical data. Categorical data were expressed as a percentage (%). The Mann-Whitney U test and t-test were used for statistical evaluation. P-values less than 0.05 were considered as statistically significant.

## RESULTS

A total of 126 healthy individuals were included in our study. Mean age of the participants was  $46.98 \pm 12.86$ . 28.6% ( $n=36$ ) of the participants were male and 71.4% ( $n=90$ ) were female. The UA levels were found to be higher in men than in women, and a statistically significant relationship was found ( $p=0.013$ ) (Table 1).

The mean BMI values of the participants was  $28.05 \pm 6.68$   $\text{kg}/\text{m}^2$  (min: 16.00- max: 47.47). The mean UA levels was  $5.21 \pm 1.19$  mg/dL (min: 2.60- max: 8.60). The distribution of other hematological parameters are shown in Table 2.

We found a significant, positive correlation between BMI and UA ( $p=0.000$ ,  $r=0.571$ ). A significant correlation was found between UA levels and triglyceride levels ( $p=0.001$ ). The relationship between UA levels and other parameters is shown in Table 3.

	Gender	n	Mean± Standard Deviation	p
UA (mg/dL)	Male	36 (%28.6)	5.76±0.97	0.013
	Female	90 (%71.4)	5.00±1.21	

\*UA: Uric acid

	Minimum	Maximum	Mean± Standard deviations
Age	18	73	46.98±12.86
BMI (kg/m <sup>2</sup> )	16.00	47.47	28.05±6.68
Glucose (mg/dL)	76	164	99.00±15.81
Urea (mg/dL)	7	26	12.54±3.587
Creatinin (mg/dL)	0.40	1.70	0.71±0.19
AST (U/L)	11	35	18.65±4.58
ALT (U/L)	6	47	16.16±7.835
LDL (mg/dL)	40	219	132.73±41.48
HDL (mg/dL)	27	70	47.95±10.60
Triglyceride (mg/dL)	46	307	146.56±64.24
Total Cholesterol (mg/dL)	88	315	207.98±46.02
Vit B12 (ng/L)	93	519	222.37±92.624
Ferritin (mg/dL)	3	235	38.46±41.45
UA (mg/dL)	2.60	8.60	5.21±1.19
Hemoglobin (g/dL)	9.7	17.4	14.05±1.47
Neutrophil (K/uL)	1.76	6.99	4.03±1.28
Lymphocyte (K/uL)	0.87	4.97	2.44±0.72
NLR	0.70	3.94	1.73±0.62
MPV (fL)	8.10	13.60	10.47±1.01

\*BMI: Body Mass Index, UA: Uric acid, NLR: Neutrophil/ Lymphocyte Ratio, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, MPV: Mean Platelet Volume

## DISCUSSION

It has not been clarified whether increased levels of UA is a risk factor for cardiovascular diseases (2). Studies have found that hyperuricemia increases when BMI increases, and that UA elevation and weight gain show parallelism (12). A study conducted in patients with chronic kidney disease showed that BMI, glucose levels and UA levels are related (13). Hikita et al. emphasized that both total and visceral fat mass and

UA levels are closely related (14). Our results are similar to the literature. Hyperuricemia is detected before obesity and diabetes in most cases, therefore it was emphasized that patients with high UA levels should be followed very closely and treatment should be started early.

A study found that there was a significant and positive correlation between UA levels and BMI in men (15). In another study, UA levels were found to be higher in men than in women, and it was stated that hyperuricemia

**Table 3.** Evaluation of UA levels and BMI and other parameters

		Uric acid
BMI	r	0.571
	p	<b>0.000</b>
NLR	r	0.003
	p	0.980
MPV	r	-0.056
	p	0.662
LDL	r	0.117
	p	0.362
HDL	r	-0.085
	p	0.508
Triglyceride	r	0.397
	p	<b>0.001</b>
Total Cholesterol	r	0.210
	p	0.099

\* UA: Uric acid, BMI: Body Mass Index, NLR: Neutrophil/ Lymphocyte Ratio, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, MPV: Mean Platelet Volume

can be considered among the indicators of metabolic syndrome (16).

In a study evaluating all age groups, it was shown that men have higher UA levels than women and that UA levels decrease with increasing age (17). In our study, UA levels were found to be higher in men than in women. A comparison based on increasing age was not included in our study. Studies have suggested that the reason for this gender difference may be estrogen, which induces UA excretion in women (18). The majority of the participants were in the reproductive period in our study and this may have caused it.

In a study evaluating the UA levels in Obstructive sleep apnea syndrome (OSAS) patients, it was found that as the severity of the disease increased, UA levels increased (19). It has been stated that UA levels should be evaluated as an independent risk factor in patients with non-alcoholic liver disease (20). Another curiosity is the relationship between different co-morbidities and the nature of their relationship.

One study showed that as HDL cholesterol levels decrease, UA values increase, and as total cholesterol and triglyceride levels increase, UA values increase (14). There are also several studies showing the relationship between high triglyceride levels and UA levels (13,21). The results of these studies are similar to those of our study. In another study, no relationship was found between UA and lipid levels. Many studies support the association between UA levels and cardiovascular risk. Nevertheless, the optimal approach to manage UA levels and their impact on comorbidities remains uncertain (10). Further studies involving larger populations are needed to provide clarity in this regard.

The main limitation of our study is the small sample size. Another limitation is that our study is planned cross-sectionally and performed in a single center, and the results cannot be generalized. Prospective studies with larger populations are needed.

## CONCLUSION

In this study, we found that serum UA levels were positively correlated with BMI and triglyceride levels. We found that UA levels in men were higher than in women. We think that UA elevation should be evaluated during the periodic health examinations.

## Ethical approval

This study has been approved by the Bolu Abant İzzet Baysal University Clinical Research Ethics Committee (approval date 24.11.2020, number 2020/284). Written informed consent was obtained from the participants.

## Author contribution

Surgical and Medical Practices: NAG; Concept: NAG; Design: NAG; Data Collection or Processing: NAG; Analysis or Interpretation: NAG; Literature Search: NAG; Writing: NAG. The author reviewed the results and approved the final version of the article.

## Source of funding

The authors declare the study received no funding.

## Conflict of interest

The authors declare that there is no conflict of interest.

## REFERENCES

1. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. *Int J Cardiol.* 2016; 213: 8-14. [\[Crossref\]](#)
2. Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. *Int J Cardiol.* 2016; 213: 4-7. [\[Crossref\]](#)
3. Ndrepepa G, Braun S, King L, et al. Uric acid and prognosis in angiography-proven coronary artery disease. *Eur J Clin Invest.* 2013; 43(3): 256-66. [\[Crossref\]](#)
4. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. *Ann Intern Med.* 1999; 131(1): 7-13. [\[Crossref\]](#)
5. Richette P, Bardin T. Gout. *Lancet.* 2010; 375(9711): 318-28. [\[Crossref\]](#)
6. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis.* 2006; 65(10): 1312-24. [\[Crossref\]](#)
7. Gliozzi M, Malara N, Muscoli S, Mollace V. The treatment of hyperuricemia. *Int J Cardiol.* 2016; 213: 23-7. [\[Crossref\]](#)
8. Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? *Curr Opin Rheumatol.* 2020; 32(1): 71-9. [\[Crossref\]](#)
9. Wu J, Lei G, Wang X, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. *Oncotarget.* 2017; 8(46): 80688-99. [\[Crossref\]](#)
10. Grassi D, Ferri L, Desideri G, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. *Curr Pharm Des.* 2013; 19(13): 2432-8. [\[Crossref\]](#)
11. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? *Clin Rheumatol.* 2017; 36(12): 2637-44. [\[Crossref\]](#)
12. Ebrahimpour P, Fakhrzadeh H, Heshmat R, Bandarian F, Larijani B. Serum uric acid levels and risk of metabolic syndrome in healthy adults. *Endocr Pract.* 2008; 14(3): 298-304. [\[Crossref\]](#)
13. řengül E, Binnetođlu E, Yılmaz A. Kronik böbrek hastalarında serum ürik asit düzeyi ile glukoz, HbA1c, lipid profili, vücut kitle indeksi ve kan basıncı arasındaki ilişki. *Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi.* 2011; 25(3): 163-8.
14. Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. *Intern Med.* 2007; 46(17): 1353-8. [\[Crossref\]](#)
15. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. *Metabolism.* 2008; 57(6): 845-52. [\[Crossref\]](#)
16. Ciarla S, Struglia M, Giorgini P, et al. Serum uric acid levels and metabolic syndrome. *Arch Physiol Biochem.* 2014; 120(3): 119-22. [\[Crossref\]](#)
17. Sun Y, Zhang H, Tian W, et al. Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study. *Aging Clin Exp Res.* 2019; 31(12): 1783-90. [\[Crossref\]](#)
18. Mumford SL, Dasharathy SS, Pollack AZ, et al. Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. *Hum Reprod.* 2013; 28(7): 1853-62. [\[Crossref\]](#)
19. Torun Parmaksız E, Salepçi B, Aktın Güngör G, Cömert S, Parmaksız E. Ürik Asit Obstrüktif Uyku Apne Sendromunda Bir Belirteç midir? *Journal of Turkish Sleep Medicine.* 2016; 3: 73-8. [\[Crossref\]](#)
20. Wei F, Li J, Chen C, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study. *Front Endocrinol (Lausanne).* 2020; 11: 179. [\[Crossref\]](#)
21. Kalyon S, Uzun H, Helvacı A, Yenice N. Hipertansiyonun hiperürisemi ile ilişkisi. *Okmeydanı Tıp Dergisi.* 2011; 27(3): 138-43.